Skip to main content
SpringerLink
Log in

Verordnungsprofil der Gynäkologen

  • Chapter
Arzneiverordnungs-Report 2004

  • 67 Accesses

Zusammenfassung

Gynäkologen stellen nach Allgemeinärzten und Internisten mit 10.911 Ärzten die drittgrößte Arztgruppe, haben aber 2003 mit Arzneimittelausgaben von 815 Mio.€ nur einen Umsatzanteil von 3,4% an den gesamten Arzneimittelausgaben im Bundesgebiet Im Verordnungsprofi! der Gynäkologen dominieren unter den 50 umsatzstärksten Arzneimitteln weiterhin 17 Präparate der Hormonersatztherapie, gefolgt von 11 hormonalen Kontrazeptiva und je 4 Präparaten der Gonadotropine, Zytostatika und Gonadoreline.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Allolio B, Arlt W (2002): DHEA treatment: myth or reality? Trends Endocrinol Metab 13:288–294.

    Article  PubMed  CAS  Google Scholar 

  • Borrelli F, Ernst E (2002): Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol 58:235–241.

    Article  PubMed  Google Scholar 

  • Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E et al (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E (2000): Second thoughts about safety of St. John’s wort. Lancet 354:2014–2016.

    Article  Google Scholar 

  • Frydman R, Howles CM, Truong F (2000): A double-blind, radomized study to compare recombi-nant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists. Hum Reprod 15: 520–525.

    Article  PubMed  CAS  Google Scholar 

  • Harvey M-A, Baker K, Wells GA (2001): Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. Am J Obstet Gynecol 185:56–61.

    Article  PubMed  CAS  Google Scholar 

  • Hay-Smith EJ, Bo Berghmans LC, Hendriks HJ, de Bie RA van Waalwijk van Doorn ES (2002): Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2002(1): CD001407.

    Google Scholar 

  • Herbison P, Hay-Smith J, Ellis G, Moore K (2003): Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Brit Med J 326: 841–847.

    Article  PubMed  CAS  Google Scholar 

  • Million Women Study Collaborators (2003): Breast Cancer and hormone-replace-ment in the Million Women Study. Lancet 362:419–427.

    Article  Google Scholar 

  • Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 87:16–23.

    Article  PubMed  CAS  Google Scholar 

  • Nathorst-Boos J, Hammar M (1997): Effect on sexual life — a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 26:15–20.

    Article  PubMed  CAS  Google Scholar 

  • Roe B, Williams K, Palmer M (2002): Bladder training for uninary incontinence in adults (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.

    Google Scholar 

  • Van Wely M, Westergaard LG, Bossuyt PMM, van der Ween F (2003a): Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 80:1086–1093.

    Article  PubMed  Google Scholar 

  • Van Wely M, Byram N, van der Ween F (2003b): Recombinant FSH in alternative doses or versus urinary gonadotrophins for ouvlation induction in subfertility aossociated with polycystic ovary Syndrome: a systematic review based on a Cochrane review. Hum Reprod 18:1143–1149.

    Article  PubMed  Google Scholar 

  • Van Wely M, Westergaard LG, Bossuyt PMM, van der Veen F (2004): Human menopausal gonadotropin versus recombinant follicle Stimulation hormone for ovarian Stimulation in assisted reproductive cycles. The Cochrane Database Syst Rev 2004(1).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2004). Verordnungsprofil der Gynäkologen. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18513-7_55

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21359-8

  • Online ISBN: 978-3-642-18513-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation